Liver Cirrhosis and Portal Hypertension

Cirrhosis and portal hypertension are tightly linked, with the latter representing the hemodynamic expression of advanced architectural distortion. Fibrosis and regenerative nodules increase intrahepatic resistance at the sinusoidal level. Concomitant endothelial dysfunction within the cirrhotic liver reduces nitric oxide, while splanchnic vasodilation increases portal inflow, together generating a hyperdynamic circulation. Clinically, this cascade manifests as splenomegaly with thrombocytopenia, collateral formation including gastroesophageal varices, ascites from renal sodium retention and capillary leak, and, in advanced stages, portosystemic shunting that contributes to hepatic encephalopathy. The hepatic venous pressure gradient (HVPG) quantifies this physiology: ≥10 mmHg (CSPH) marks a threshold beyond which first decompensation becomes likely, and ≥12 mmHg heightens bleeding risk. These thresholds inform risk stratification and therapy. Evidence-based management targets both the drivers and consequences of portal hypertension. Nonselective beta-blockers reduce portal inflow and the incidence of first decompensation in CSPH, while endoscopic variceal ligation directly manages varices. Acute variceal bleeding requires bundled care—antibiotics, vasoactive agents, urgent endoscopy—with early TIPS considered in high-risk presentations. For refractory ascites or recurrent bleeding, TIPS offers effective portal decompression but increases encephalopathy risk; patient selection is critical. Standardized care for decompensation includes sodium restriction with diuretics, large-volume paracentesis with albumin when needed, prevention and early treatment of SBP, and lactulose with rifaximin for encephalopathy. Lifestyle measures—complete alcohol abstinence, vaccination against hepatitis A and B, optimized nutrition with adequate protein, and avoidance of NSAIDs—support stability. Transplantation remains definitive for end-stage or recurrently decompensated disease, guided by MELD-Na. Monitoring uses imaging and endoscopy, as well as noninvasive criteria (liver stiffness plus platelet count) to prioritize who needs variceal screening. Across this pathway, early recognition of red flags—hematemesis, melena, fever with ascites, progressive confusion, severe dyspnea from tense ascites, or rapidly declining urine output—triggers emergency evaluation.

Eastern traditions interpret the cirrhosis–portal hypertension connection through patterns of disrupted flow and fluid metabolism. In Traditional Chinese Medicine (TCM), chronic Liver Qi stagnation and Blood stasis reflect the impeded movement within the liver network; Damp-Heat and Spleen Qi deficiency account for fluid accumulation and digestive weakness, echoing ascites and malnutrition in modern terms. Treatment principles seek to move Qi and Blood, transform Dampness, and support the Spleen. Acupuncture points selected to regulate Liver–Spleen harmony and calm the spirit may help with abdominal distention, sleep, and anxiety, indirectly supporting adherence to medical regimens. Formula-based approaches have explored antifibrotic potential; Fuzheng Huayu, which contains botanicals such as Salvia miltiorrhiza and Schisandra, has shown signals of benefit in hepatic fibrosis in small trials. In Ayurveda, Yakrit Roga involves deranged Pitta and Kapha with impaired Agni (digestive fire), leading to fluid retention and tissue degeneration; care focuses on gentle detoxification, diet regulation, and rasayana (rejuvenative) support. An integrative plan harmonizes these perspectives with biomedical safety. Core elements—complete alcohol avoidance, low-sodium whole-food diets, adequate protein to prevent sarcopenia, vaccination, and movement practices (yoga, breathing, walking)—are compatible across traditions and have supportive evidence for symptom relief and quality of life. Herbal adjuncts such as milk thistle (silymarin) are widely used; while some studies report improved liver enzymes, convincing evidence for survival or prevention of decompensation is limited. Moreover, herb–drug interactions and herb-induced liver injury are well documented; certain botanicals (e.g., kava, chaparral, comfrey; high-dose licorice) are unsafe in liver disease. Thus, any complementary therapy should be individualized, sourced from reputable suppliers, and coordinated with the hepatology team. The shared goal is pragmatic: reduce the drivers of ongoing injury, ease symptom burden, and maintain stability while disease-modifying medical and procedural therapies (beta-blockers, endoscopic therapy, TIPS, transplantation) address the hemodynamic core of portal hypertension.